Precision or personalized medicine holds tremendous promise for more than just the patients whom it aims to treat. It also represents an area of broadening interest and opportunity among investors and innovators seeking to capitalize on its market potential. Given the complex and rapidly changing nature of the space, however, questions abound from those who are currently launching or are seeking to launch a precision medicine venture about how best to navigate the financing challenges in order to successfully develop and commercialize their novel technologies and products.
Representing the private investor, serial entrepreneur, and public company perspectives, this panel will address some of the key questions and considerations for attracting capital in the space, including:
John Doulis, MD, Chief Informatics and Information Officer, MedCare Investment Funds
Manuel J. Glynias, President and Chief Executive Officer, GenomOncology
Samuel D. Riccitelli, Former President and Chief Executive Officer, Signal Genetics
MODERATOR: Jeffrey S. Karan, Managing Partner, WaveEdge Capital